Literature DB >> 32766947

Evaluating H3F3A K27M and G34R/V somatic mutations in a cohort of pediatric brain tumors of different and rare histologies.

Vinicius Fernandes Oliveira1, Graziella Ribeiro De Sousa2, Antonio Carlos Dos Santos3, Fabiano Pinto Saggioro4, Helio Rubens Machado5, Ricardo Santos de Oliveira6, Luiz Gonzaga Tone7, Elvis Terci Valera8.   

Abstract

PURPOSE: Somatic mutations on H3 histone are currently considered a genetic hallmark for midline pediatric high-grade gliomas (HGGs). Yet, different tumor histologies have been occasionally described to carry these mutations. Since histone modifications can lead to major epigenetic changes with direct impact on prognosis and treatment, we thought to investigate the occurrence of H3F3A K27M and G34R/V mutations in a cohort of pediatric tumors which included HGGs, low-grade gliomas, ependymomas, medulloblastomas, and a series of rare brain tumor lesions of different histologies.
METHODS: A total of 82 fresh-frozen pediatric brain tumor samples were evaluated. PCR or RT-PCR followed by Sanger sequencing for the exon 2 of H3F3A (containing both K27 and G34 hotspots) were obtained and aligned to human genome. Loss of trimethylation mark (H3K27me3) in H3F3A/K27M-mutant samples was confirmed by immunohistochemistry.
RESULTS: We found H3F3A/K27M mutation in 2 out of 9 cases of HGGs; no H3F3A/K27M mutations were detected in low-grade gliomas (27), ependymomas (n = 10), medulloblastomas (n = 21), or a series of rare pediatric brain tumors which included meningiomas, dysembryoplastic neuroepithelial tumors (DNETs), central nervous system (CNS) germ-cell tumors, choroid plexus tumors, cortical hamartoma, subcortical tubers, and schwannomas (n = 15). H3F3A/G34R/V mutation was not observed in any of the samples.
CONCLUSIONS: Our investigation reinforces the low frequency of H3F3A somatic mutations outside the HGG setting. Interestingly, an atypical focal brainstem glioma carrying H3F3A K27M mutation that showed protracted clinical course with late-onset tumor progression was identified.

Entities:  

Keywords:  Brain cancer; Epigenetics; Histone; Midline gliomas

Mesh:

Substances:

Year:  2020        PMID: 32766947     DOI: 10.1007/s00381-020-04852-8

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  27 in total

1.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.

Authors:  Jeremy Schwartzentruber; Andrey Korshunov; Xiao-Yang Liu; David T W Jones; Elke Pfaff; Karine Jacob; Dominik Sturm; Adam M Fontebasso; Dong-Anh Khuong Quang; Martje Tönjes; Volker Hovestadt; Steffen Albrecht; Marcel Kool; Andre Nantel; Carolin Konermann; Anders Lindroth; Natalie Jäger; Tobias Rausch; Marina Ryzhova; Jan O Korbel; Thomas Hielscher; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Martin Ebinger; Martin U Schuhmann; Wolfram Scheurlen; Arnulf Pekrun; Michael C Frühwald; Wolfgang Roggendorf; Christoph Kramm; Matthias Dürken; Jeffrey Atkinson; Pierre Lepage; Alexandre Montpetit; Magdalena Zakrzewska; Krzystof Zakrzewski; Pawel P Liberski; Zhifeng Dong; Peter Siegel; Andreas E Kulozik; Marc Zapatka; Abhijit Guha; David Malkin; Jörg Felsberg; Guido Reifenberger; Andreas von Deimling; Koichi Ichimura; V Peter Collins; Hendrik Witt; Till Milde; Olaf Witt; Cindy Zhang; Pedro Castelo-Branco; Peter Lichter; Damien Faury; Uri Tabori; Christoph Plass; Jacek Majewski; Stefan M Pfister; Nada Jabado
Journal:  Nature       Date:  2012-01-29       Impact factor: 49.962

2.  Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome.

Authors:  Pooja Panwalkar; Jonathan Clark; Vijay Ramaswamy; Debra Hawes; Fusheng Yang; Christopher Dunham; Stephen Yip; Juliette Hukin; Yilun Sun; Matthew J Schipper; Lukas Chavez; Ashley Margol; Melike Pekmezci; Chan Chung; Adam Banda; Jill M Bayliss; Sarah J Curry; Mariarita Santi; Fausto J Rodriguez; Matija Snuderl; Matthias A Karajannis; Amanda M Saratsis; Craig M Horbinski; Anne-Sophie Carret; Beverly Wilson; Donna Johnston; Lucie Lafay-Cousin; Shayna Zelcer; David Eisenstat; Marianna Silva; Katrin Scheinemann; Nada Jabado; P Daniel McNeely; Marcel Kool; Stefan M Pfister; Michael D Taylor; Cynthia Hawkins; Andrey Korshunov; Alexander R Judkins; Sriram Venneti
Journal:  Acta Neuropathol       Date:  2017-07-21       Impact factor: 17.088

3.  H3 K27M mutations are extremely rare in posterior fossa group A ependymoma.

Authors:  Scott Ryall; Miguel Guzman; Samer K Elbabaa; Betty Luu; Stephen C Mack; Michal Zapotocky; Michael D Taylor; Cynthia Hawkins; Vijay Ramaswamy
Journal:  Childs Nerv Syst       Date:  2017-06-16       Impact factor: 1.475

4.  High frequency of H3 K27M mutations in adult midline gliomas.

Authors:  Azadeh Ebrahimi; Marco Skardelly; Martin U Schuhmann; Martin Ebinger; David Reuss; Manuela Neumann; Ghazaleh Tabatabai; Patricia Kohlhof-Meinecke; Jens Schittenhelm
Journal:  J Cancer Res Clin Oncol       Date:  2019-01-04       Impact factor: 4.553

5.  Paediatric diffuse leptomeningeal tumor with glial and neuronal differentiation harbouring chromosome 1p/19q co-deletion and H3.3 K27M mutation: unusual molecular profile and its therapeutic implications.

Authors:  Aruna Nambirajan; Vaishali Suri; Sweta Kedia; Keshav Goyal; Prit Benny Malgulwar; Gaurav Khanna; Prateek Kumar Panda; Sheffali Gulati; Ajay Garg; Mehar Chand Sharma
Journal:  Brain Tumor Pathol       Date:  2018-07-20       Impact factor: 3.298

6.  Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone.

Authors:  Hidetaka Yamamoto; Takeshi Iwasaki; Yuichi Yamada; Yoshihiro Matsumoto; Hiroshi Otsuka; Masato Yoshimoto; Kenichi Kohashi; Kenichi Taguchi; Ryohei Yokoyama; Yasuharu Nakashima; Yoshinao Oda
Journal:  Hum Pathol       Date:  2017-12-12       Impact factor: 3.466

7.  Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.

Authors:  Michael Karremann; Gerrit H Gielen; Marion Hoffmann; Maria Wiese; Niclas Colditz; Monika Warmuth-Metz; Brigitte Bison; Alexander Claviez; Dannis G van Vuurden; André O von Bueren; Marco Gessi; Ingrid Kühnle; Volkmar H Hans; Martin Benesch; Dominik Sturm; Rolf-Dieter Kortmann; Andreas Waha; Torsten Pietsch; Christof M Kramm
Journal:  Neuro Oncol       Date:  2018-01-10       Impact factor: 12.300

8.  Detection of H3K27M mutation in cases of brain stem subependymoma.

Authors:  Kun Yao; Zejun Duan; Yin Wang; Mingshan Zhang; Tao Fan; Bin Wu; Xueling Qi
Journal:  Hum Pathol       Date:  2018-10-30       Impact factor: 3.466

9.  Characteristics of H3 K27M-mutant gliomas in adults.

Authors:  David Meyronet; Maud Esteban-Mader; Charlotte Bonnet; Marie-Odile Joly; Emmanuelle Uro-Coste; Alexandra Amiel-Benouaich; Fabien Forest; Cécilia Rousselot-Denis; Fanny Burel-Vandenbos; Véronique Bourg; Jacques Guyotat; Tanguy Fenouil; Anne Jouvet; Jérôme Honnorat; François Ducray
Journal:  Neuro Oncol       Date:  2017-08-01       Impact factor: 12.300

10.  Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas.

Authors:  Gang Wu; Alberto Broniscer; Troy A McEachron; Charles Lu; Barbara S Paugh; Jared Becksfort; Chunxu Qu; Li Ding; Robert Huether; Matthew Parker; Junyuan Zhang; Amar Gajjar; Michael A Dyer; Charles G Mullighan; Richard J Gilbertson; Elaine R Mardis; Richard K Wilson; James R Downing; David W Ellison; Jinghui Zhang; Suzanne J Baker
Journal:  Nat Genet       Date:  2012-01-29       Impact factor: 38.330

View more
  1 in total

1.  Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.

Authors:  Débora Cabral de Carvalho Corrêa; Francine Tesser-Gamba; Indhira Dias Oliveira; Nasjla Saba da Silva; Andrea Maria Capellano; Maria Teresa de Seixas Alves; Patrícia Alessandra Dastoli; Sergio Cavalheiro; Silvia Regina Caminada de Toledo
Journal:  J Cancer Res Clin Oncol       Date:  2021-10-09       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.